Trial · NCT04843761
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
NCT04843761, Phase 3, Completed, National Institute of Allergy and Infectious Diseases (NIAID); results first posted 2025-10-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19. Trials, record NCT04843761. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04843761
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
- NCT number
- NCT04843761
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 473 participants, actual
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- Covid19
- Interventions
- Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
- First posted
- 2021-04-14
- Last updated
- 2025-10-24
- Results first posted
- 2025-10-24
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Substudy Analysis Cohorts | Screening, within 24 hours | The primary analysis for each agent was to pool across applicable groups to compare each agent vs. matched placebo. Refer to the agent-specific records for results by agent (H1 \[Aviptadil\]: NCT06729606; H2 \[Remdesivir\]: NCT06729593). |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Substudy Analysis Cohorts | Screening, within 24 hours | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Substudy Analysis Cohorts | Stratum 1 - Aviptadil + Remdesivir | Aviptadil substudy analysis cohort | 18 | Participants | |
| Substudy Analysis Cohorts | Stratum 1 - Aviptadil +Remdesivir Placebo | Aviptadil substudy analysis cohort | 21 | Participants | |
| Substudy Analysis Cohorts | Stratum 1 - Aviptadil Placebo + Remdesivir | Aviptadil substudy analysis cohort | 25 | Participants | |
| Substudy Analysis Cohorts | Stratum 1 - Aviptadil Placebo + Remdesivir Placebo | Aviptadil substudy analysis cohort | 21 | Participants | |
| Substudy Analysis Cohorts | Stratum 2 - Aviptadil | Aviptadil substudy analysis cohort | 12 | Participants | |
| Substudy Analysis Cohorts | Stratum 2 - Aviptadil Placebo | Aviptadil substudy analysis cohort | 11 | Participants | |
| Substudy Analysis Cohorts | Stratum 3 - Remdesivir | Aviptadil substudy analysis cohort | 0 | Participants | |
| Substudy Analysis Cohorts | Stratum 3 - Remdesivir Placebo | Aviptadil substudy analysis cohort | 0 | Participants | |
| Substudy Analysis Cohorts | Stratum 4 - Aviptadil | Aviptadil substudy analysis cohort | 183 | Participants | |
| Substudy Analysis Cohorts | Stratum 4 - Aviptadil Placebo | Aviptadil substudy analysis cohort | 180 | Participants |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow30
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Stratum 1 - Aviptadil + Remdesivir | 18 | |
| Overall Study | STARTED | Stratum 1 - Aviptadil +Remdesivir Placebo | 21 | |
| Overall Study | STARTED | Stratum 1 - Aviptadil Placebo + Remdesivir | 25 | |
| Overall Study | STARTED | Stratum 1 - Aviptadil Placebo + Remdesivir Placebo | 21 | |
| Overall Study | STARTED | Stratum 2 - Aviptadil | 12 | |
| Overall Study | STARTED | Stratum 2 - Aviptadil Placebo | 11 | |
| Overall Study | STARTED | Stratum 3 - Remdesivir | 1 | |
| Overall Study | STARTED | Stratum 3 - Remdesivir Placebo | 1 | |
| Overall Study | STARTED | Stratum 4 - Aviptadil | 183 | |
| Overall Study | STARTED | Stratum 4 - Aviptadil Placebo | 180 |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals30
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Stratum 1 - Aviptadil + Remdesivir | 0 | 0 |
| Total, all-cause mortality | Stratum 1 - Aviptadil +Remdesivir Placebo | 0 | 0 |
| Total, all-cause mortality | Stratum 1 - Aviptadil Placebo + Remdesivir | 0 | 0 |
| Total, all-cause mortality | Stratum 1 - Aviptadil Placebo + Remdesivir Placebo | 0 | 0 |
| Total, all-cause mortality | Stratum 2 - Aviptadil | 0 | 0 |
| Total, all-cause mortality | Stratum 2 - Aviptadil Placebo | 0 | 0 |
| Total, all-cause mortality | Stratum 3 - Remdesivir | 0 | 0 |
| Total, all-cause mortality | Stratum 3 - Remdesivir Placebo | 0 | 0 |
| Total, all-cause mortality | Stratum 4 - Aviptadil | 0 | 0 |
| Total, all-cause mortality | Stratum 4 - Aviptadil Placebo | 0 | 0 |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 adverse event totalsPapers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04843761
GET https://conductscience.org/api/trials/v1/NCT04843761/flow?page=2